Skip to Main Content

Paper Details

CCL17 acts as a novel therapeutic target in pathological cardiac hypertrophy and heart failure.
J Exp Med
17
2022
Ang II, C-C motif chemokine ligand 17, CCL17, Ccll7, T cell subsets, age-related diseases, angiotensin II, anti-CCL17 neutralizing antibody, cardiac dysfunction, cardiac hypertrophy, chemokine CCL17, fibrosis, heart failure, patients
Author NameAffiliation
Toshiko TanakaNational Institute on Aging, National Institutes of Health
Toshiko TanakaNational Institute on Aging, National Institutes of Health
Luigi FerrucciNational Institute on Aging, National Institutes of Health
Luigi FerrucciNational Institute on Aging, National Institutes of Health
  • 1 - 4

Datasets

Release 1.2